Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH
A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of terguride tablets, administered orally for 3 months, to patients with fibromyalgia.
Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo. Having finished this proof-of-conceptstudy it is intended that patients will continuously be treated in an open labelextension on a voluntary basis. - TERPAH
100 项与 ErgoNex Pharma GmbH 相关的临床结果
0 项与 ErgoNex Pharma GmbH 相关的专利(医药)
100 项与 ErgoNex Pharma GmbH 相关的药物交易
100 项与 ErgoNex Pharma GmbH 相关的转化医学